KEROS THERAPEUTICS, INC. (KROS) Return on equity 2020–2025
KEROS THERAPEUTICS, INC. (KROS) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
28.7%FY2025 · since FY2020: -17.3% → 28.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 28.7% | +61.5 pp |
| FY2024 | -32.8% | +13.3 pp |
| FY2023 | -46.1% | -8.3 pp |
| FY2022 | -37.7% | -13.6 pp |
| FY2021 | -24.2% | -6.8 pp |
| FY2020 | -17.3% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice